Daniel R. Chevallard, Chief Financial Officer of LENZ Therapeutics, Inc., filed a Form 4 on November 3, 2026, disclosing the acquisition of a stock option covering 652,063 shares of common stock in connection with his role as Interim President and CEO.

Key Highlights

  • Reporting person: Daniel R. Chevallard, Chief Financial Officer of LENZ Therapeutics, Inc. (NASDAQ:LENZ)
  • Transaction date: October 30, 2026, with the form filed November 3, 2026
  • Security acquired: A stock option (right to buy) covering 652,063 shares of common stock, with an exercise price of $3.05
  • Transaction code: A (acquisition); price of derivative security reported as $0
  • Expiration date: October 29, 2036
  • Vesting structure: Four equal tranches of 25% each, with commencement dates of November 1, 2026; February 1, 2027; May 1, 2027; and August 1, 2027, each vesting in full one year after commencement
  • Post-transaction holdings: 652,063 derivative securities beneficially owned directly following the reported transaction

Chevallard Stock Option Award Tied to Interim CEO Service at LENZ Therapeutics

According to the filing, Chevallard acquired a stock option to purchase 652,063 shares of LENZ Therapeutics common stock on October 30, 2026, at an exercise price of $3.05 per share. The option was recorded with a transaction code of "A" (acquisition) and a price of $0 for the derivative security itself. The option expires on October 29, 2036, and Chevallard reported direct ownership of 652,063 derivative securities following the transaction.

The filing's explanation of responses states that the vesting schedule is contingent on Chevallard "serving as the Issuer's Interim President and CEO through each applicable date." The option vests in four equal tranches: 25% commencing November 1, 2026, and vesting in full on November 1, 2027; 25% commencing February 1, 2027, and vesting in full on February 1, 2028; 25% commencing May 1, 2027, and vesting in full on May 1, 2028; and 25% commencing August 1, 2027, and vesting in full on August 1, 2028.

According to the filing, if Chevallard ceases to serve as Interim President and CEO for any reason, "any tranche for which the vesting commencement date has not yet occurred will be forfeited, and any tranche for which the vesting commencement date has occurred will remain eligible to vest." The form was signed by Evert Schimmelpennink as Attorney-in-Fact on November 3, 2026. No non-derivative securities transactions were reported in Table I of the filing.

What Was Disclosed

Daniel R. Chevallard, CFO of LENZ Therapeutics, disclosed the acquisition of a stock option for 652,063 shares at $3.05 per share, tied to his service as Interim President and CEO, with vesting across four annual tranches through August 2028.